Patents by Inventor Jayson Michael Rieger

Jayson Michael Rieger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12290651
    Abstract: Applicator devices (1), kits, systems, and methods of using such devices for treating one or more body surface conditions (e.g., warts, Molluscum contagiosum, conjunctivitis, otitis) are provided. The applicator device facilitates topical administration of a controllable amount of a pharmaceutical composition to a desired area of an affected body surface (e.g., skin, eye, ear, nose, mouth, anus, vagina). The applicator device includes an ampule (40) containing the pharmaceutical composition, the ampule being positioned within a tube (50). Squeezing the tube breaks the ampule, releasing the pharmaceutical composition. The applicator device includes a filter (30) that permits passage of fluid and inhibits passage of broken ampule shards. The applicator device includes a dispensing tip (20) through which the pharmaceutical composition passes.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: May 6, 2025
    Assignee: Verrica Pharmaceuticals Inc.
    Inventors: Matthew Gene Davidson, Jayson Michael Rieger, Eugene Scavola, Paul Daly, Howard Welgus
  • Patent number: 12233042
    Abstract: Methods of treating one or more skin lesions using cantharidin as well as associated compositions, treatment regimens, kits, devices, and systems are provided. A method of treating a subject having one or more skin lesions may involve administering a composition comprising cantharidin to one or more skin lesions. The method may allow for the efficacious treatment of the skin lesion(s) with minimal or no adverse side effects (e.g., severe adverse side effects, permanent damage of the dermal tissue, scarring, excessive blistering of skin surrounding the lesion, elevated plasma cantharidin concentration, systemic exposure to cantharidin). The efficacy and/or safety of the treatment may be due, to certain features of the composition and/or prolonged exposure of the skin lesion(s) to cantharidin. The methods described herein may be used for a wide variety of cutaneous disorders, including skin disorders that primarily affect the epidermis of skin.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: February 25, 2025
    Assignee: Verrica Pharmaceuticals Inc.
    Inventors: Howard Welgus, Matthew Gene Davidson, Jayson Michael Rieger
  • Publication number: 20250051412
    Abstract: The present disclosure describes a dosing regimen of an IL-10F129S expression construct for treating an inflammatory joint disease (e.g., osteoarthritis) in a subject. Methods are provided for treating an inflammatory joint disease in a subject by injecting a first dose and second dose of a composition comprising an IL-10F129S expression construct into an inflamed joint of the subject according to a dosing regimen wherein the two doses of the expression construct are administered to a subject approximately 150-360 days apart. The present disclosure also provides kits comprising a first and second dose of an IL-10F129S expression construct. The kits may be useful for treating an inflammatory joint disease in a subject.
    Type: Application
    Filed: December 16, 2022
    Publication date: February 13, 2025
    Applicant: Xalud Therapeutics, Inc.
    Inventors: Jayson Michael Rieger, David Glover, Howard Rutman, Stephen Collins, Diem Nguyen
  • Publication number: 20210401793
    Abstract: Methods of treating one or more skin lesions using cantharidin as well as associated compositions, treatment regimens, kits, devices, and systems are provided. A method of treating a subject having one or more skin lesions may involve administering a composition comprising cantharidin to one or more skin lesions. The method may allow for the efficacious treatment of the skin lesion(s) with minimal or no adverse side effects (e.g., severe adverse side effects, permanent damage of the dermal tissue, scarring, excessive blistering of skin surrounding the lesion, elevated plasma cantharidin concentration, systemic exposure to cantharidin). The efficacy and/or safety of the treatment may be due, to certain features of the composition and/or prolonged exposure of the skin lesion(s) to cantharidin. The methods described herein may be used for a wide variety of cutaneous disorders, including skin disorders that primarily affect the epidermis of skin.
    Type: Application
    Filed: September 10, 2021
    Publication date: December 30, 2021
    Applicant: Verrica Pharmaceuticals Inc.
    Inventors: Howard Welgus, Matthew Gene Davidson, Jayson Michael Rieger
  • Patent number: 11147790
    Abstract: Methods of treating one or more skin lesions using cantharidin as well as associated compositions, treatment regimens, kits, devices, and systems are provided. A method of treating a subject having one or more skin lesions may involve administering a composition comprising cantharidin to one or more skin lesions. The method may allow for the efficacious treatment of the skin lesion(s) with minimal or no adverse side effects (e.g., severe adverse side effects, permanent damage of the dermal tissue, scarring, excessive blistering of skin surrounding the lesion, elevated plasma cantharidin concentration, systemic exposure to cantharidin). The efficacy and/or safety of the treatment may be due, to certain features of the composition and/or prolonged exposure of the skin lesion(s) to cantharidin. The methods described herein may be used for a wide variety of cutaneous disorders, including skin disorders that primarily affect the epidermis of skin.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: October 19, 2021
    Assignee: Verrica Pharmaceuticals Inc.
    Inventors: Howard Welgus, Matthew Gene Davidson, Jayson Michael Rieger
  • Publication number: 20210138214
    Abstract: Applicator devices (1), kits, systems, and methods of using such devices for treating one or more body surface conditions (e.g., warts, Molluscum contagiosum, conjunctivitis, otitis) are provided. The applicator device facilitates topical administration of a controllable amount of a pharmaceutical composition to a desired area of an affected body surface (e.g., skin, eye, ear, nose, mouth, anus, vagina). The applicator device includes an ampule (40) containing the pharmaceutical composition, the ampule being positioned within a tube (50). Squeezing the tube breaks the ampule, releasing the pharmaceutical composition. The applicator device includes a filter (30) that permits passage of fluid and inhibits passage of broken ampule shards. The applicator device includes a dispensing tip (20) through which the pharmaceutical composition passes.
    Type: Application
    Filed: June 15, 2018
    Publication date: May 13, 2021
    Applicant: Verrica Pharmaceuticals, Inc.
    Inventors: Matthew Gene Davidson, Jayson Michael Rieger, Eugene Scavola, Paul Daly, Howard Welgus
  • Publication number: 20200155498
    Abstract: Methods of treating one or more skin lesions using cantharidin as well as associated compositions, treatment regimens, kits, devices, and systems are provided. A method of treating a subject having one or more skin lesions may involve administering a composition comprising cantharidin to one or more skin lesions. The method may allow for the efficacious treatment of the skin lesion(s) with minimal or no adverse side effects (e.g., severe adverse side effects, permanent damage of the dermal tissue, scarring, excessive blistering of skin surrounding the lesion, elevated plasma cantharidin concentration, systemic exposure to cantharidin). The efficacy and/or safety of the treatment may be due, to certain features of the composition and/or prolonged exposure of the skin lesion(s) to cantharidin. The methods described herein may be used for a wide variety of cutaneous disorders, including skin disorders that primarily affect the epidermis of skin.
    Type: Application
    Filed: June 6, 2018
    Publication date: May 21, 2020
    Applicant: Verrica Pharmaceuticals, Inc
    Inventors: Howard Welgus, Matthew Gene Davidson, Jayson Michael Rieger
  • Patent number: D900312
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: October 27, 2020
    Assignee: Verrica Pharmaceuticals, Inc.
    Inventors: Matthew Gene Davidson, Jayson Michael Rieger, Eugene Scavola, Paul Daly
  • Patent number: D1036656
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: July 23, 2024
    Assignee: Verrica Pharmaceuticals Inc.
    Inventors: Matthew Gene Davidson, Jayson Michael Rieger, Eugene Scavola, Paul Daly